Burosumab should be considered as an effective and safe alternative strategy for FGF23-mediated hypophosphatemia in FD/MAS for those who either cannot tolerate or do not respond to the association of vitamin D analog and phosphate supplements. Here, FGF23 is linked to hypophosphatemia.